The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical ...

Superior efficacy at 12 weeks was seen with the frontline combination of abemaciclib and endocrine therapy vs standard ...

Abemaciclib has been awarded the status for the treatment of patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer, on the strength of a phase I trial ...

The drug is approved in combination with an aromatase inhibitor as adjuvant therapy for breast cancer patients at high risk of recurrence.

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...

The drug joins abemaciclib (Verzenio) as approved CDK4/6 inhibitors in this setting, but the broader indication for ...

Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population. The ...

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) ...

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase I for Metastatic Renal Cell Carcinoma.

POETIC-A is investigating whether adding the drug abemaciclib alongside hormone therapy can help prevent higher risk early breast cancer from returning. Abemaciclib works by blocking molecules which ...